Trials / Active Not Recruiting
Active Not RecruitingNCT05143229
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
Phase I Trial Of Alpelisib Plus Sacituzumab Govitecan In Patients With Metastatic Or Locally Recurrent HER2-Negative Breast Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- University of Kansas Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alpelisib | PI3K inhibitor |
| DRUG | Sacituzumab govitecan | Trop-2-directed antibody and topoisomerase inhibitor drug conjugate |
Timeline
- Start date
- 2022-03-28
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2021-12-03
- Last updated
- 2025-10-06
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05143229. Inclusion in this directory is not an endorsement.